Leadership Overview
GC Biopharma has 5 executives leading key functions including finance, marketing, strategy, and operations.
Driven by innovation, GC Biopharma is dedicated to advancing human health through its specialized development, manufacturing, and distribution of critical biopharmaceutical products, solidifying its position as a global leader.
Driven by innovation, GC Biopharma is dedicated to advancing human health through its specialized development, manufacturing, and distribution of critical biopharmaceutical products, solidifying its position as a global leader.
Leadership Roles at GC Biopharma
Jin Pyun - Chief Executive Officer, Gc Ventures, A Subsidiary of Gc Holdings (US)
Jin Pyun, the Chief Executive Officer, Gc Ventures, A Subsidiary of Gc Holdings (US) at GC Biopharma, directs strategic investment and innovation ventures for the parent company within the United States market. This executive leadership position focuses on identifying and nurturing emerging biopharmaceutical technologies and companies that align with GC Biopharma's core mission. Pyun oversees the operational execution of Gc Ventures, managing a portfolio of investments aimed at accelerating the development of novel therapies and expanding the company's technological capabilities. The Chief Executive Officer's responsibilities include fostering strategic alliances, evaluating potential acquisitions, and driving synergistic growth opportunities. Jin Pyun's vision is instrumental in positioning GC Biopharma at the forefront of biopharmaceutical innovation through targeted venture capital activities.
Seongyeol Kim - Chief Financial Officer
Seongyeol Kim, the Chief Financial Officer at GC Biopharma, directs all financial operations and strategic fiscal planning. This leadership role involves managing the company's capital structure, optimizing investment portfolios, and ensuring robust financial reporting across all global subsidiaries. Kim oversees budgeting, forecasting, and risk management, aligning financial strategies with GC Biopharma's long-term growth objectives in the biopharmaceutical sector. The Chief Financial Officer's oversight extends to treasury functions, investor relations, and securing funding for research and development initiatives. Seongyeol Kim's expertise is critical in navigating the complex financial landscape of the pharmaceutical industry, driving profitability and sustainable economic performance. This executive ensures fiscal discipline and supports strategic expansion through meticulous financial stewardship.
Eun Huh - President
Eun Huh, the President at GC Biopharma, holds a senior executive position overseeing critical operational functions and strategic initiatives. This leadership role involves driving operational excellence across the company's manufacturing and distribution networks, ensuring the efficient production and delivery of vaccines and plasma-derived therapies. Huh collaborates closely with other C-suite executives to implement corporate strategies, focusing on enhancing production capacity and maintaining the highest quality standards. The President's purview includes optimizing supply chain logistics and managing key internal departments to support GC Biopharma's global market presence. Eun Huh's strategic direction is vital for maintaining the company's competitive edge and ensuring the reliable supply of essential biopharmaceutical products to patients worldwide.
Francis Kim - President
Francis Kim, the President at GC Biopharma, directs significant aspects of the company's strategic growth and operational expansion. This executive leadership role focuses on advancing GC Biopharma's research and development pipeline, particularly in the areas of novel vaccines and plasma-derived treatments. Kim oversees cross-functional teams dedicated to product innovation, clinical trials, and regulatory affairs, ensuring alignment with global healthcare standards. The President's responsibilities include fostering key relationships with research institutions and healthcare providers to accelerate therapeutic advancements. Francis Kim's leadership is crucial in driving the company's mission to develop life-saving biopharmaceutical solutions and expand access to critical medical treatments across international markets.
Kwangsu Lee - Global Chief Marketing Officer, Business Development Head of & External Manufacturing
Kwangsu Lee, the Global Chief Marketing Officer, Business Development Head of & External Manufacturing at GC Biopharma, spearheads global market strategies and drives business development initiatives. This multifaceted role encompasses identifying new market opportunities, forging strategic partnerships, and overseeing the company's external manufacturing relationships to ensure product supply chain integrity. Lee directs all marketing campaigns, product launches, and brand management efforts, focusing on expanding GC Biopharma's international footprint in the vaccine and plasma-derived therapy markets. The Head of External Manufacturing ensures seamless collaboration with third-party manufacturers, maintaining stringent quality standards. Kwangsu Lee's leadership is pivotal in translating scientific innovation into commercial success and securing global market penetration for GC Biopharma's vital pharmaceutical products.
Explore Leadership Teams in Manufacturing
GSK plc is a British multinational pharmaceutical and biotechnology company headquartered in London, United Kingdom. Established in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, GSK is the tenth-largest pharmaceutical company globally. The company discovers, develops, manufactures, and delivers medicines and vaccines with a research and development focus on four primary therapeutic areas: respiratory, immunology and inflammation, oncology, HIV, and infectious diseases. GSK's product portfolio includes specialty medicines, vaccines, and general medicines targeting conditions such as HIV, respiratory diseases, cancer, immuno-inflammation, anti-viral, central nervous system disorders, metabolic conditions, cardiovascular disease, urogenital conditions, anti-bacterial treatments, dermatology, and rare diseases. The company also offers over-the-counter products for pain relief, oral health, nutrition, skin health, and gastrointestinal diseases. GSK has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. In July 2024, the company moved its global headquarters to New Oxford Street in central London, positioning itself within the city's Knowledge Quarter near world-class science and academic institutions including the Francis Crick Institute and King's College London. The new headquarters houses approximately 3,000 employees including the global leadership team and teams supporting research and development, supply chain, commercial operations, and corporate functions. GSK sells its products through wholesalers, pharmacies, hospitals, physicians, and other healthcare groups globally, aiming to positively impact the health of 2.5 billion people by the end of the decade.
Company Leadership MD
CJ
GN
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions. The company focuses on research and development of treatments across multiple therapeutic areas to address various medical conditions and improve patient outcomes worldwide. Novartis maintains a significant presence in scientific research, with extensive operations spanning across Europe, North America, Asia, and other global regions.
Company Leadership EM
WS
DC
DC
Baxter International Inc. provides a portfolio of renal and hospital products. The company operates through two segments, Hospital Products and Renal. The Hospital Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics, and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies. The Renal segment provides products to treat end-stage renal disease, irreversible kidney failure, and acute kidney therapies. This segment offers products for various treatment continuums, such as technologies and therapies for peritoneal dialysis, hemodialysis, continuous renal replacement therapy, and additional dialysis services. The company sells its products for use in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors offices, and by patients at home under physician supervision.
Company Leadership
JA
JF
LP
Ajanta Pharma is an Indian multinational pharmaceutical company that develops, manufactures, and markets a broad range of branded and generic pharmaceutical products for both domestic and international markets. The company’s portfolio spans multiple therapeutic areas, including cardiology, dermatology, anti‑infectives, pain management, and ophthalmology, with products distributed through its own sales and marketing networks as well as through partnerships. Ajanta Pharma focuses on research, regulatory compliance, and quality manufacturing to support access to affordable medicines, while also expanding its presence in global markets across Asia, Africa, and other regions. The company’s operations encompass formulation development, compliance with international standards, and strategic market expansion to serve diverse healthcare needs.
Company Leadership SA
AK
RJ
PV
Frequently Asked Questions Regarding GC Biopharma Top Executives and Leadership Team
